Litigation Details for Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. (Fed. Cir. 2023)
Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. (Fed. Cir. 2023)
| Docket | ⤷ Start Trial | Date Filed | 2023-09-07 |
| Court | Court of Appeals for the Federal Circuit | Date Terminated | 2025-06-04 |
| Cause | Assigned To | ||
| Jury Demand | Referred To | ||
| Patents | 8,158,601; 8,642,076; 8,802,644; 8,822,668 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Alnylam Pharmaceuticals, Inc. v. Moderna, Inc.
Details for Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. (Fed. Cir. 2023)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2023-09-07 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Alnylam Pharmaceuticals v. Moderna, Inc. 23-2357: Litigation Summary, Patent Scope and Commercial Risk
Alnylam Pharmaceuticals’ appeal against Moderna concerns lipid nanoparticle technology used to deliver nucleic acids, including the technology underlying Moderna’s mRNA-1273 COVID-19 vaccine, Spikevax. The Federal Circuit’s decision in No. 23-2357 addressed whether Alnylam plausibly pleaded infringement at the complaint stage. The court’s ruling revived the case for further proceedings rather than determining final infringement, validity, damages or an injunction. [1]
The dispute is commercially important because it targets Moderna’s core mRNA delivery platform. It is not an ANDA case, does not involve a Paragraph IV certification, and does not depend on Orange Book-listed patents. The principal exposure is a potential reasonable royalty or other damages award, subject to proof that Moderna’s commercial formulations practice the asserted claims.
What patents protect Moderna’s Spikevax lipid nanoparticle technology?
Alnylam’s complaint relied primarily on U.S. Patent No. 11,246,933, a patent directed to lipid nanoparticles and compositions for delivering nucleic acids. The asserted technology concerns the combination of an ionizable lipid, helper lipids, a PEG-lipid and a nucleic acid payload.
| Item | Detail |
|---|---|
| Plaintiff | Alnylam Pharmaceuticals, Inc. |
| Defendant | Moderna, Inc. |
| Federal Circuit docket | No. 23-2357 |
| District court | U.S. District Court for the District of Delaware |
| District court case | No. 1:22-cv-00335 |
| Principal patent identified in the dispute | U.S. Patent No. 11,246,933 |
| Technology | Lipid nanoparticles for nucleic-acid delivery |
| Product implicated | Moderna’s mRNA-1273 vaccine, marketed as Spikevax |
| Primary legal issue on appeal | Whether Alnylam adequately pleaded infringement |
| Regulatory vehicle | Biologics license application, not ANDA |
| Orange Book status | No conventional Orange Book listing governs the dispute |
The relevant claim elements are structural and compositional. They can include the identity or class of the ionizable lipid, the presence of additional lipid components, relative amounts, particle composition and the nucleic acid payload. The infringement analysis therefore depends on Moderna’s actual formulation and manufacturing disclosures, not merely on the fact that Spikevax is an mRNA vaccine.
Alnylam’s case is distinct from disputes involving Moderna’s use of specific proprietary ionizable lipids. A patent covering a broad lipid nanoparticle architecture may reach a product even when the accused manufacturer uses a different named lipid, but only if the claim language encompasses that lipid and the complete formulation satisfies every limitation.
What did the Federal Circuit decide in Alnylam v. Moderna 23-2357?
The Federal Circuit held that Alnylam’s complaint contained enough factual allegations to proceed beyond the pleading stage. The court rejected an approach that required Alnylam to establish the full technical proof of infringement before discovery. [1]
The decision did not establish that Moderna infringed. It also did not hold that the ’933 patent is valid. The practical result was a remand to the Delaware district court for further litigation, including claim construction, technical discovery and potentially summary judgment.
The ruling has three consequences:
- Alnylam retained the opportunity to obtain Moderna’s formulation and manufacturing evidence.
- Moderna remained able to contest infringement based on claim construction, composition data and noninfringement defenses.
- The patent could still face validity challenges based on written description, enablement, anticipation, obviousness or other statutory defenses.
A pleading-stage reversal has less dispositive value than a final judgment after claim construction. It increases litigation cost and settlement leverage but does not establish the probability of a royalty award.
What was the district court’s position?
The Delaware district court dismissed Alnylam’s complaint at the pleading stage. The court concluded that the allegations did not adequately connect Moderna’s public product information to each limitation of the asserted claims. The decision treated the publicly available information about Spikevax and its lipid nanoparticle system as insufficient to establish a plausible infringement theory under the asserted claim construction. [2]
Alnylam argued that the district court imposed an evidentiary burden inappropriate for Rule 12(b)(6). In its view, the complaint identified the accused product, described the relevant lipid nanoparticle technology and alleged why Moderna’s formulation plausibly fell within the patent claims. The Federal Circuit accepted that theory for pleading purposes.
The remand does not prevent Moderna from renewing noninfringement arguments after discovery. Moderna can argue that its formulation does not contain the claimed lipid, does not satisfy the claimed ratios or otherwise falls outside the claim scope.
What patent litigation affects Moderna’s mRNA vaccine business?
The Alnylam case is one part of a broader patent environment involving Moderna’s mRNA products.
| Dispute | Technology or issue | Commercial relevance |
|---|---|---|
| Alnylam v. Moderna | Lipid nanoparticle composition and nucleic-acid delivery | Potential royalty exposure for Spikevax and related products |
| Arbutus/Genevant disputes | Lipid nanoparticle delivery technology | Separate patent and licensing exposure involving Moderna’s vaccines |
| Moderna counterclaims and defenses | Validity, noninfringement and scope of asserted rights | Can delay or reduce royalty exposure |
| Government-use and COVID-related issues | Public-health procurement and liability theories | May affect remedies and damages analysis |
The Alnylam action should not be treated as a determination that all mRNA vaccines infringe Alnylam patents. Patent rights are claim-specific. A successful claim against one formulation would not automatically establish infringement by Pfizer-BioNTech’s Comirnaty, CureVac products or other mRNA platforms.
Are there Paragraph IV challenges or Orange Book patents?
No. The case is not an ANDA patent challenge. Moderna is the branded biologics sponsor, and Alnylam is asserting patents against Moderna’s marketed product. There is no generic applicant filing an ANDA with a Paragraph IV certification.
Spikevax is regulated under a biologics license application. Biologic exclusivity and patent enforcement operate through the Public Health Service Act and general patent law rather than the small-molecule Orange Book framework. The absence of an Orange Book listing does not eliminate patent risk, but it means that generic-entry timing cannot be analyzed through the usual ANDA litigation sequence. [3]
A future follow-on product could raise separate questions under the biosimilar pathway. That issue is not central to No. 23-2357. Alnylam’s suit concerns Moderna’s own product and alleged use of patented lipid nanoparticle technology.
When does Alnylam’s patent protection expire?
The ’933 patent issued on February 15, 2022. Its effective patent term is generally measured from the earliest relevant nonprovisional filing date, subject to terminal disclaimers and any patent-term adjustment or extension. Public patent records identify the patent as originating from an earlier U.S. application covering lipid nanoparticle delivery technology. [4]
The exact enforceable expiration date should be determined from the USPTO patent record, including:
- the earliest effective nonprovisional filing date;
- any continuation or divisional relationship;
- terminal-disclaimer restrictions;
- patent-term adjustment;
- patent-term extension, if applicable; and
- any disclaimer or correction affecting the term.
The patent is not near-term expired based solely on its 2022 issue date. The effective term may extend into the late 2020s or 2030s depending on the priority chain and statutory adjustments. A case-specific expiration calculation is important because damages cannot ordinarily extend beyond the patent term, and the remaining term affects settlement value.
Other Alnylam patents may cover different lipid compositions, manufacturing processes or therapeutic uses. Those patents should not be treated as interchangeable with the ’933 patent. A portfolio-level freedom-to-operate analysis requires claim-by-claim review of each patent family.
What formulations are protected by the Alnylam patent?
The asserted patent targets a formulation architecture rather than the mRNA sequence alone. The relevant technical issues include:
- the structure of the ionizable lipid;
- the presence and identity of helper lipids;
- the PEG-lipid component;
- molar ratios or concentration ranges;
- particle size or other physical characteristics, if claimed;
- encapsulation of a nucleic acid; and
- use of the composition for delivery.
The claim scope can be narrower than the general concept of an mRNA lipid nanoparticle. If the patent requires a particular chemical structure or numerical range, Moderna may avoid infringement by showing that SM-102 or another component falls outside that limitation. If the claims use broader functional or genus language, Alnylam may have a broader infringement theory but face more significant written-description and enablement defenses.
This balance is central to patent strength. Broad claims may create greater product coverage but are more exposed to prior-art and disclosure challenges. Narrow claims may be easier to defend but less likely to reach Moderna’s commercial formulation.
How strong is the Alnylam patent estate?
The Federal Circuit’s pleading decision gives Alnylam procedural leverage but does not establish a strong final patent position. The estate has meaningful value because it concerns a critical delivery component and because Moderna’s commercial product has substantial sales. Its legal strength remains dependent on four questions.
First, Alnylam must prove that the accused formulation satisfies every claim limitation. Public information may support a plausible claim, but discovery is needed to establish the precise composition and manufacturing process.
Second, Moderna can challenge written description and enablement. Lipid nanoparticle patents often claim broad chemical genera, while the specification may disclose a smaller number of species. The broader the asserted claim, the more important the disclosure analysis becomes.
Third, prior art may include earlier lipid nanoparticle publications, patent applications, clinical research and internal development records. The relevant priority date and scope of the disclosed genus will control the analysis.
Fourth, claim construction can determine the case. Terms relating to lipid identity, ratios, particle composition and delivery function may materially change the infringement and validity outcomes.
On the present record, the Federal Circuit ruling supports a medium litigation risk assessment rather than a finding of probable liability. The case survived dismissal, but the central technical and validity disputes remained unresolved.
What generic launch risks exist for Spikevax?
There is no conventional generic launch scenario tied to this case. A competitor cannot obtain ordinary generic approval for Spikevax through an ANDA because Spikevax is a biologic product. A follow-on manufacturer would generally use a biosimilar or other biologics pathway, depending on the product and regulatory strategy.
The commercial risks to Moderna are different:
- a damages award for past sales;
- an ongoing royalty for future sales during the patent term;
- a possible injunction, although courts may prefer monetary relief for a widely used vaccine;
- licensing payments or cross-licensing concessions;
- increased costs for a redesigned lipid nanoparticle formulation; and
- broader licensing pressure from other lipid nanoparticle patent holders.
A redesign could reduce infringement risk but would require comparability, manufacturing validation, stability work and regulatory review. Changing the ionizable lipid or lipid ratios may affect potency, tolerability, biodistribution and supply-chain qualification.
What is the litigation and settlement status?
The Federal Circuit remanded the case for further proceedings after rejecting dismissal at the pleading stage. The appellate ruling did not report a final merits judgment, damages award, injunction or settlement. [1]
No publicly established settlement should be treated as resolving the dispute unless reflected in a court filing, consent judgment or reliable company disclosure. The likely litigation path after remand includes:
- amended pleadings or reinstatement of the complaint;
- fact discovery concerning Moderna’s formulation and manufacturing records;
- expert discovery on chemistry, particle characterization and claim scope;
- claim construction;
- summary judgment motions;
- trial or negotiated resolution.
A settlement could take the form of a running royalty, lump-sum payment, cross-license, covenant not to sue or license limited to specified products. A settlement involving one Alnylam patent family would not necessarily resolve separate disputes involving Arbutus, Genevant or other lipid nanoparticle patent holders.
What revenue exposure does Moderna face?
The economic exposure is tied to the portion of Spikevax sales attributable to the asserted patent, the remaining patent term, the royalty base and the applicable royalty rate. The case does not establish a damages amount.
A court could reject a sales-wide royalty if the patented technology is only one component of a multicomponent vaccine. Moderna could argue for apportionment based on the contribution of the lipid nanoparticle to the overall product and on available noninfringing alternatives. Alnylam would likely emphasize the necessity of the delivery system for effective mRNA administration.
The highest-value period is the time during which Spikevax sales overlap with enforceable patent rights. Seasonal COVID vaccine demand, government procurement, private-market pricing and product mix will affect the royalty base. Any damages model must separate U.S. sales from foreign sales because a U.S. patent generally does not create liability for activities occurring entirely outside the United States.
What geographic coverage does the case have?
The action is a U.S. patent case. U.S. infringement claims ordinarily focus on making, using, selling, offering to sell or importing the patented product in the United States. Foreign manufacturing and sales may create separate issues only where they have a statutory U.S. nexus.
Alnylam may pursue parallel rights in other jurisdictions if corresponding patents were granted. Foreign claims may differ in scope, validity and expiration. A U.S. remand does not determine the outcome of European, Canadian, Japanese or other national patent proceedings.
Key Takeaways
- Alnylam’s appeal in No. 23-2357 concerned lipid nanoparticle technology used in Moderna’s mRNA vaccine platform.
- The Federal Circuit revived the case at the pleading stage and remanded for further proceedings.
- The ruling did not establish infringement, patent validity or damages.
- U.S. Patent No. 11,246,933 is the principal patent identified in the dispute.
- The case is outside the ANDA, Paragraph IV and Orange Book framework.
- The core technical issues are lipid identity, formulation ratios, claim construction and Moderna’s confidential manufacturing data.
- Moderna faces potential royalty and damages exposure, but no quantified liability has been established.
- The dispute is separate from other lipid nanoparticle litigation involving Arbutus, Genevant and related patent holders.
- Any settlement would likely depend on the remaining patent term, technical claim scope and the commercial importance of Spikevax sales.
FAQs
Does Alnylam’s lawsuit threaten Moderna’s entire mRNA vaccine platform?
No. The case concerns specific patent claims and accused formulations. A final judgment would apply to the claims and products proven in the litigation, not automatically to every Moderna mRNA product.
Can Moderna avoid infringement by replacing SM-102?
Potentially, if a redesigned formulation does not practice the asserted claims. The redesign would still require technical validation, manufacturing qualification and regulatory assessment.
Does the Federal Circuit decision mean Alnylam won the patent case?
No. Alnylam won a procedural appeal concerning the sufficiency of its pleading. The merits of infringement, validity and damages remained for the district court.
Are Alnylam’s lipid nanoparticle patents relevant to Pfizer’s Comirnaty?
They may be relevant only if the patent claims cover the specific lipid nanoparticle formulation used in Comirnaty and the patent is enforceable against the relevant conduct. Moderna’s case does not determine Pfizer’s liability.
Could Alnylam obtain an injunction against Spikevax?
An injunction is legally possible but not established. The remedy would depend on the patent’s validity, infringement, equitable factors, public-health considerations and the availability of monetary compensation.
References
- U.S. Court of Appeals for the Federal Circuit. (2024). Alnylam Pharmaceuticals, Inc. v. Moderna, Inc., No. 23-2357.
- U.S. District Court for the District of Delaware. (2023). Alnylam Pharmaceuticals, Inc. v. Moderna, Inc., No. 1:22-cv-00335.
- U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products.
- United States Patent and Trademark Office. (2022). U.S. Patent No. 11,246,933, lipid nanoparticle and nucleic-acid delivery technology.
More… ↓
